Biopharmaceutical CDMO Market Growth Fueled by Advanced Therapies

Biopharmaceutical CDMO Market Size, Trends and Growth with Insights

The global biopharmaceutical CDMO market size is calculated at US$ 20.55 billion in 2024, grew to US$ 22.34 billion in 2025, and is projected to reach around US$ 46.98 billion by 2034. The market is expanding at a CAGR of 8.73% between 2025 and 2034.

The growing demand for biologics, advanced therapies, and vaccines is increasing the demand for biopharmaceutical CDMOs. This, in turn, is increasing their use for various purposes for the development of a variety of products. AI is also being used to enhance their workflow, where companies are also developing and using new AI platforms. These advancements are driving the use of these services across various regions. The companies are also collaborating and launching their new products, which, in turn, are contributing to the market growth.

Key Takeaways

• Biopharmaceutical CDMO industry poised to reach USD 20.55 billion by 2024.
• Forecasted to grow to USD 46.98 billion by 2034.
• Expected to maintain a CAGR of 8.73% from 2025 to 2034.
• North America held approximately a 41% share in the global biopharmaceutical CDMO market in 2024.
• Asia Pacific is expected to be the fastest-growing region from 2025-2034.
• By service type, the commercial manufacturing segment held an approximate 44% share in the market in 2024.
• By service type, the fill–finish & packaging segment is expected to be the fastest growing during the forecast period.
• By product type, the monoclonal antibodies (mAbs) segment held approximately a 40% share in the market in 2024.
• By product type, the cell & gene therapies segment is expected to be the fastest growing during the forecast period.
• By technology platform type, the mammalian cell culture segment held an approximate 47% share in the market in 2024.
• By technology platform type, the cell & gene therapy platforms segment is expected to be the fastest growing during the forecast period.
• By end user, the large pharmaceutical companies segment held an approximate 49% share in the global biopharmaceutical CDMO market in 2024.
• By end user, the biotechnology companies segment is expected to be the fastest growing during the forecast period.

Executive Summary Table

What is a Biopharmaceutical CDMO?

The biopharmaceutical CDMO market is driven by growth in the demand for specialized manufacturing capabilities and increasing complexities of biologic drugs. The Biopharmaceutical Contract Development and Manufacturing Organization (CDMO) provides outsourced services across the development and production lifecycle of biopharmaceuticals and offers expertise in biologics such as monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapies, and RNA-based therapies. Their services span cell line development, process optimization, analytical testing, clinical and commercial-scale manufacturing, fill–finish, and packaging.

The market is driven by rising demand for biologics, growing biotech start-ups with limited in-house manufacturing, cost-efficiency of outsourcing, complex biomanufacturing processes, and rapid innovation in advanced therapies. Increasing regulatory scrutiny and the trend toward modular and flexible facilities also shape the CDMO landscape.

Biopharmaceutical CDMO Market Outlook

• Industry Growth Overview: The growing demand for outsourced services and growth in the robust pipeline of complex biologic drugs are increasing the demand for biopharmaceutical CDMO services by various companies. At the same time, the expanding industries, advancements in manufacturing technologies, and increasing demand for specialized expertise are also increasing their use.
• Sustainability Trends: Due to growing regulatory and government regulations, the biopharmaceutical CDMOs are increasingly adopting sustainability practices. They are focusing on utilizing green chemistry, minimizing manufacturing waste, and solvent use, while encouraging the use of renewable energy sources and investing in sustainable packaging solutions.
• Major Investors: The pharmaceutical, biotechnological companies, and financial investors, similar to the private equity firms, are actively investing in the biopharmaceutical CDMOs. The major investors are Lonza, WuXi Biologics, and Thermo Fisher Scientific, who are expanding their services and facilities globally.

AI Technological Shifts in the Biopharmaceutical CDMO Market

The use of AI platforms in the biopharmaceutical CDMO is increasing to predict the drug potency and safety. At the same time, it is also being used for drug discovery and development, as well as for quality control. Moreover, it also enhances the packaging and production of large molecules, as well as conducts automated visual inspection.

For instance,

• In September 2025, a collaboration between Insilico Medicine, ChemExpress, and Mabwell Bioscience was announced, where the Pharma.AI platform, used to develop novel payload-linkers with innovative structures and high selectivity of Insilico, an extensive library of molecular building blocks, reference compounds, and robust technical support of  ChemExpress, and access to its proprietary ADC technology platform, hundreds of monoclonal antibodies, and multi-specific antibodies of Mabwell will be combined in this collaboration.
• In May 2025, a collaboration between Lonza and IBM to utilize AI technologies to develop models and to implement an AI-trained automated visual inspection system, which will reject products not meeting the standards.

Trends in the Biopharmaceutical CDMO Market

Growing innovations: The growth in the development of biologics, biosimilars, vaccines, etc, is increasing the demand for biopharmaceutical CDMO services. Additionally, growing advanced therapies are also increasing their use for expertise and advanced facilities. These advancements are further supported by the investments and new collaborations among the companies.

For instance,

• In September 2025, a collaboration between Mycenax Biotech Inc., which is a leading biologics CDMO, and Spera Pharma Inc. was announced. This collaboration will focus on the drug substance production, linker/payload synthesis, and aseptic fill-finish, and will provide solutions for antibody-drug conjugates (ADCs) and bioconjugates.
• In June 2025, with a plan to acquire Agenus Inc.'s US-based biologics CMC facilities, Zydus Lifesciences Ltd will enter into the global biologics contract development and manufacturing organization (CDMO) business. Moreover, strategic investment in US-based manufacturing for biologics was also announced by Zydus.

Table: Biopharmaceutical CDMOs and Their Achievements

Segmental Insights

How the Commercial Manufacturing Segment Dominated the Biopharmaceutical CDMO Market in 2024?

By service type, the commercial manufacturing segment led the market with approximately 44% share in 2024, due to growing demand for biologics driving their production rates. At the same time, the growing outsourcing trends to minimize operational costs have also increased their use. Moreover, to comply with the GMP standards, they were preferred.

By service type, the fill–finish & packaging segment is expected to show the highest growth during the predicted time. Due to the growing development of gene therapies, vaccines, and other injectables, the use of biopharmaceutical CDMO for these services is increasing. Additionally, growing demand for personalized treatment options and outsourcing trends are increasing their use.

Which Product Type Segment Held the Dominating Share of the Biopharmaceutical CDMO Market in 2024? 

By product type, the monoclonal antibodies (mAbs) segment held the dominating share of approximately 40% in the market in 2024, as they were used for the treatment of a wide range of diseases. This increased their production and distribution, which increased the demand for biopharmaceutical CDMOs. Moreover, their growing innovations also contributed to their increased use.

By product type, the cell & gene therapies segment is expected to show the fastest growth rate during the predicted time. These therapies are providing curative options to various rare diseases, which is increasing their demand. This, in turn, is increasing the use of biopharmaceutical CDMO services to accelerate the R&D and production.

What Made Mammalian Cell Culture the Dominant Segment in the Biopharmaceutical CDMO Market in 2024?

By technology platform type, the mammalian cell culture segment dominated the market with approximately 47% share in 2024, as they were essential for biopharmaceutical development. They also enhanced the quality and action of the proteins developed. Thus, they were used in the development of a wide range of products.

By technology platform type, the cell & gene therapy platforms segment is expected to show the highest growth during the upcoming years. Due to the growing use of these therapies, their use is increasing, which is enhancing the demand for their platforms. They are also being used for clinical trials.

Why Did the Large Pharmaceutical Companies Segment Dominate in the Biopharmaceutical CDMO Market in 2024?

By end user, the large pharmaceutical companies segment held the largest share of approximately 49% in the market in 2024, driven by the growth in R&D. At the same time, the expanding biologic and biosimilar pipeline is also increasing the use of biopharmaceutical CDMO services. They also supported the product's large-scale manufacturing.

By end user, the biotechnology companies segment is expected to show the fastest growth rate during the upcoming years. The growth in the innovations of advanced therapies is increasing the use of biopharmaceutical CDMO services. They are being used for product manufacturing, R&D, and growing outsourcing trends.

Regional Insights

Large Biopharma Ecosystems Drive North America

North America dominated the biopharmaceutical CDMO market with approximately a 41% share in 2024. North America consisted of well-developed, large biopharmaceutical ecosystems, which increased the use of biopharmaceutical CDMOs. At the same time, growing R&D and healthcare investments also encouraged their use. Moreover, the presence of advanced infrastructure also increased the production of various biologics, which contributed to the market growth.

U.S. Biopharmaceutical CDMO Market Trends

Due to the growing production of biologics in the U.S., the demand for biopharmaceutical CDMO services is increasing, along with their manufacturing. They are also used to develop products that comply with regulatory standards, as they provide expertise. Moreover, the government support is also promoting their use.

The Canada Biopharmaceutical CDMO Market Trends

The biopharmaceutical services are being used for R&D in Canada. At the same time, to enhance their GMP manufacturing, clinical trials, etc., are also increasing their use. Additionally, the growth in the use of cell and gene therapies and R&D investments is increasing their demand for various purposes.

Expanding Industries Boost Asia Pacific

Asia Pacific is expected to host the fastest-growing biopharmaceutical CDMO market during the forecast period. Asia Pacific is experiencing an expansion in the biopharmaceutical industry, which in turn is increasing the demand for biopharmaceutical CDMO services. This growth is due to the growing demand for advanced therapies, vaccines, and biologics. The growing government and private sector investments are also encouraging their use. Thus, this is promoting the market growth.

What is the Country-Level Analysis?

• In February 2025, expansion from USD 7 billion to USD 14 billion by 2028 is anticipated for the Contract Development and Manufacturing Organization (CDMO) market of India. The growth in the biopharmaceutical sector due to emerging modalities like antibody-drug conjugates (ADCs), nucleic acid therapeutics, and cell and gene therapy, along with the growth in the active pharmaceutical ingredients (API) and generic drug manufacturing.
• In September 2024, Eurofins CDMO is developing a new biologics manufacturing facility with the use of the investments provided by the Strategic Innovation Fund (SIF) of Canada. Moreover, $22.4 million will be provided by the government to Eurofins, where the plant will develop protein therapies and monoclonal antibodies.

Biopharmaceutical CDMO Market Value Chain Analysis

R&D

The R&D of biopharmaceutical CDMO focuses on process development, formulation improvement, manufacturing techniques enhancements, and optimization of new modalities like cell and gene therapies.

Key Players: Lonza Group, WuXi Biologics, Thermo Fisher Scientific, Catalent Inc.

Packaging and Serialization

The use of unique identifiers for individual drug packages to ensure end-to-end traceability and authenticity throughout their supply chain to ensure regulatory compliance and prevent counterfeiting is involved in the biopharmaceutical CDMOs.

Key Players: Lonza Group, WuXi Biologics, Thermo Fisher Scientific, Catalent Inc.

Patient Support and Services

The biopharmaceutical CDMO does not directly provide patient support and services, but the client company offers various patient support programs.

Key Players: Lonza Group, WuXi Biologics, Thermo Fisher Scientific, Catalent Inc., Samsung Biologics.

Top vendors and Their Offerings

• Lonza Group: The company is a dedicated CDMO that offers its services to its clients and their patients. They develop various life-improving and lifesaving treatments.
• Samsung Biologics: The company is a fully integrated, end-to-end CDMO service provider focusing on cell line development to final aseptic fill/finish and laboratory testing services. Moreover, they are expanding their capabilities, promoting their innovations.
• Catalent Inc.: The company is responsible for optimizing product development as it offers comprehensive integrated solutions, providing more flexibility. It also focuses on optimization of launch and full life cycle supply to the patients.
• Fujifilm Diosynth Biotechnologies: The company focuses on the development of biologics, vaccines, and advanced therapies. They are expanding their collaboration to transform the industry through their Partners for Life mindset.
• WuXi Biologics: The company supports the biologics development by providing open-access and integrated technology platforms.

Which are the Top Companies in the Biopharmaceutical CDMO Market?

• Thermo Fisher Scientific (Patheon)
• Boehringer Ingelheim BioXcellence
• Rentschler Biopharma SE
• AbbVie Contract Manufacturing
• AGC Biologics
• Charles River Laboratories (Biologics CDMO arm)
• Emergent BioSolutions
• ICONOVO Biologics
• Vibalogics (Recipharm)
• KBI Biopharma
• Ajinomoto Bio-Pharma Services
• Samsung Bioepis (collaborative manufacturing)
• Minaris Regenerative Medicine
• Binex Co., Ltd.
• Evotec SE (Biologics CDMO division)

What are the Recent Developments in the Biopharmaceutical CDMO Market?

• In September 2025, another product for severe autoimmune disease will be developed at the FUJIFILM Biotechnologies plant present in Holly Springs. The company has signed an agreement with Argenx SE, where it will develop the drug substance for efgartigimod as Argenx’s treatment for severe autoimmune disease.
• In September 2025, two next-generation Glutamine Synthetase knockout CHO-K1 expression systems and a double knockout ADCC+ platform were launched by Abzena, which is a leading end-to-end integrated CDMO for complex biologics and bioconjugates. It will be used for afucosylated proteins, and will expand their AbZelectPROTM cell line development (CDL) platform.

Segments Covered in the Report

By Service Type

• Process Development (Upstream & Downstream)
• Analytical & Quality Testing
• Clinical Manufacturing
• Commercial Manufacturing
• Fill–Finish & Packaging
• Others (Regulatory Support, Tech Transfer, Stability Testing)

By Product Type

• Monoclonal Antibodies (mAbs)
• Recombinant Proteins
• Vaccines
• Cell & Gene Therapies
• RNA-based Therapies (mRNA, siRNA)
• Others (Peptides, Fusion Proteins, Biosimilars)

By Technology Platform 

• Mammalian Cell Culture (CHO, HEK293, etc.)
• Microbial Fermentation (E. coli, Yeast)
• Cell & Gene Therapy Platforms (Viral Vectors, CAR-T, TCR, AAV, Lentivirus)
• RNA Manufacturing Platforms (mRNA, saRNA)
• Others (Plant-based Expression, Cell-free Systems)

By End User

• Biotechnology Companies
• Large Pharmaceutical Companies
• Academic & Research Institutions
• Contract Research Organizations (CROs) leveraging CDMOs

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait